APO Research
Talk to an analyst

APO RESEARCH · REPORT

Liver Cirrhosis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Liver Cirrhosis Therapeutics Market Outlook and Growth Opportunities 2026

20 December 2025199 pages

Choose your research edition.

Industry ResearchLiver Cirrhosis Therapeutics Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Liver Cirrhosis Therapeutics Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Liver Cirrhosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liver Cirrhosis Therapeutics Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Liver Cirrhosis Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Liver Cirrhosis Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Liver Cirrhosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Liver Cirrhosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Liver Cirrhosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Liver Cirrhosis Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Liver Cirrhosis Therapeutics market include Bristol-Myers Squibb, Conatus Pharmaceuticals, Gilead Sciences, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, NGM Biopharmaceuticals, Norgine and Pharmicell, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Liver Cirrhosis Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Liver Cirrhosis Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Liver Cirrhosis Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liver Cirrhosis Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Liver Cirrhosis Therapeutics Segment by Company

Bristol-Myers Squibb

Conatus Pharmaceuticals

Gilead Sciences

Gwo Xi Stem Cell Applied Technology

Instituto Grifols

Intercept Pharmaceuticals

NGM Biopharmaceuticals

Norgine

Pharmicell

Salix Pharmaceuticals

Stempeutics Research

GlaxoSmithKline

Roche

Merck

Johnson & Johnson

Liver Cirrhosis Therapeutics Segment by Type

Oral Liver Cirrhosis Therapeutics Drugs

Injection Liver Cirrhosis Therapeutics Drugs

Liver Cirrhosis Therapeutics Segment by Application

Hospitals

Clinics

Other

Liver Cirrhosis Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Liver Cirrhosis Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Liver Cirrhosis Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Liver Cirrhosis Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Liver Cirrhosis Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liver Cirrhosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liver Cirrhosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liver Cirrhosis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Liver Cirrhosis Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Liver Cirrhosis Therapeutics industry.

Chapter 3: Detailed analysis of Liver Cirrhosis Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Liver Cirrhosis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Liver Cirrhosis Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Liver Cirrhosis Therapeutics Industry Trends Table 2. Liver Cirrhosis Therapeutics Industry Drivers Table 3. Liver Cirrhosis Therapeutics Industry Opportunities and Challenges Table 4. Liver Cirrhosis Therapeutics Industry Restraints Table 5. Global Liver Cirrhosis Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Liver Cirrhosis Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Liver Cirrhosis Therapeutics Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Liver Cirrhosis Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global Liver Cirrhosis Therapeutics Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Liver Cirrhosis Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Liver Cirrhosis Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global Liver Cirrhosis Therapeutics Company, Product Type & Application Table 13. Global Liver Cirrhosis Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Liver Cirrhosis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Liver Cirrhosis Therapeutics Drugs Table 18. Significant Companies of Injection Liver Cirrhosis Therapeutics Drugs Table 19. Global Liver Cirrhosis Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Liver Cirrhosis Therapeutics Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Liver Cirrhosis Therapeutics Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Liver Cirrhosis Therapeutics Sales Volume Share by Type (2021-2026) Table 23. Global Liver Cirrhosis Therapeutics Sales Volume Share by Type (2027-2032) Table 24. Global Liver Cirrhosis Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Liver Cirrhosis Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Liver Cirrhosis Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Liver Cirrhosis Therapeutics Sales Value Share by Type (2021-2026) Table 28. Global Liver Cirrhosis Therapeutics Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Clinics Table 31. Significant Companies of Other Table 32. Global Liver Cirrhosis Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 33. Global Liver Cirrhosis Therapeutics Sales Volume by Application (2021-2026) & (W Units) Table 34. Global Liver Cirrhosis Therapeutics Sales Volume by Application (2027-2032) & (W Units) Table 35. Global Liver Cirrhosis Therapeutics Sales Volume Share by Application (2021-2026) Table 36. Global Liver Cirrhosis Therapeutics Sales Volume Share by Application (2027-2032) Table 37. Global Liver Cirrhosis Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Liver Cirrhosis Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Liver Cirrhosis Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Liver Cirrhosis Therapeutics Sales Value Share by Application (2021-2026) Table 41. Global Liver Cirrhosis Therapeutics Sales Value Share by Application (2027-2032) Table 42. Global Liver Cirrhosis Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 43. Global Liver Cirrhosis Therapeutics Sales by Region (2021-2026) & (W Units) Table 44. Global Liver Cirrhosis Therapeutics Sales Market Share by Region (2021-2026) Table 45. Global Liver Cirrhosis Therapeutics Sales by Region (2027-2032) & (W Units) Table 46. Global Liver Cirrhosis Therapeutics Sales Market Share by Region (2027-2032) Table 47. Global Liver Cirrhosis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Liver Cirrhosis Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Liver Cirrhosis Therapeutics Sales Value Share by Region (2021-2026) Table 50. Global Liver Cirrhosis Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Liver Cirrhosis Therapeutics Sales Value Share by Region (2027-2032) Table 52. Global Liver Cirrhosis Therapeutics Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Liver Cirrhosis Therapeutics Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Liver Cirrhosis Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Global Liver Cirrhosis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Liver Cirrhosis Therapeutics Sales by Country (2021-2026) & (W Units) Table 57. Global Liver Cirrhosis Therapeutics Sales Market Share by Country (2021-2026) Table 58. Global Liver Cirrhosis Therapeutics Sales by Country (2027-2032) & (W Units) Table 59. Global Liver Cirrhosis Therapeutics Sales Market Share by Country (2027-2032) Table 60. Global Liver Cirrhosis Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Liver Cirrhosis Therapeutics Sales Value Market Share by Country (2021-2026) Table 62. Global Liver Cirrhosis Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Liver Cirrhosis Therapeutics Sales Value Market Share by Country (2027-2032) Table 64. Bristol-Myers Squibb Company Information Table 65. Bristol-Myers Squibb Business Overview Table 66. Bristol-Myers Squibb Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Bristol-Myers Squibb Liver Cirrhosis Therapeutics Product Portfolio Table 68. Bristol-Myers Squibb Recent Development Table 69. Conatus Pharmaceuticals Company Information Table 70. Conatus Pharmaceuticals Business Overview Table 71. Conatus Pharmaceuticals Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Conatus Pharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio Table 73. Conatus Pharmaceuticals Recent Development Table 74. Gilead Sciences Company Information Table 75. Gilead Sciences Business Overview Table 76. Gilead Sciences Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Gilead Sciences Liver Cirrhosis Therapeutics Product Portfolio Table 78. Gilead Sciences Recent Development Table 79. Gwo Xi Stem Cell Applied Technology Company Information Table 80. Gwo Xi Stem Cell Applied Technology Business Overview Table 81. Gwo Xi Stem Cell Applied Technology Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Gwo Xi Stem Cell Applied Technology Liver Cirrhosis Therapeutics Product Portfolio Table 83. Gwo Xi Stem Cell Applied Technology Recent Development Table 84. Instituto Grifols Company Information Table 85. Instituto Grifols Business Overview Table 86. Instituto Grifols Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Instituto Grifols Liver Cirrhosis Therapeutics Product Portfolio Table 88. Instituto Grifols Recent Development Table 89. Intercept Pharmaceuticals Company Information Table 90. Intercept Pharmaceuticals Business Overview Table 91. Intercept Pharmaceuticals Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Intercept Pharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio Table 93. Intercept Pharmaceuticals Recent Development Table 94. NGM Biopharmaceuticals Company Information Table 95. NGM Biopharmaceuticals Business Overview Table 96. NGM Biopharmaceuticals Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. NGM Biopharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio Table 98. NGM Biopharmaceuticals Recent Development Table 99. Norgine Company Information Table 100. Norgine Business Overview Table 101. Norgine Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Norgine Liver Cirrhosis Therapeutics Product Portfolio Table 103. Norgine Recent Development Table 104. Pharmicell Company Information Table 105. Pharmicell Business Overview Table 106. Pharmicell Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Pharmicell Liver Cirrhosis Therapeutics Product Portfolio Table 108. Pharmicell Recent Development Table 109. Salix Pharmaceuticals Company Information Table 110. Salix Pharmaceuticals Business Overview Table 111. Salix Pharmaceuticals Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Salix Pharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio Table 113. Salix Pharmaceuticals Recent Development Table 114. Stempeutics Research Company Information Table 115. Stempeutics Research Business Overview Table 116. Stempeutics Research Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Stempeutics Research Liver Cirrhosis Therapeutics Product Portfolio Table 118. Stempeutics Research Recent Development Table 119. GlaxoSmithKline Company Information Table 120. GlaxoSmithKline Business Overview Table 121. GlaxoSmithKline Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. GlaxoSmithKline Liver Cirrhosis Therapeutics Product Portfolio Table 123. GlaxoSmithKline Recent Development Table 124. Roche Company Information Table 125. Roche Business Overview Table 126. Roche Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Roche Liver Cirrhosis Therapeutics Product Portfolio Table 128. Roche Recent Development Table 129. Merck Company Information Table 130. Merck Business Overview Table 131. Merck Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Merck Liver Cirrhosis Therapeutics Product Portfolio Table 133. Merck Recent Development Table 134. Johnson & Johnson Company Information Table 135. Johnson & Johnson Business Overview Table 136. Johnson & Johnson Liver Cirrhosis Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Johnson & Johnson Liver Cirrhosis Therapeutics Product Portfolio Table 138. Johnson & Johnson Recent Development Table 139. Key Raw Materials Table 140. Raw Materials Key Suppliers Table 141. Liver Cirrhosis Therapeutics Distributors List Table 142. Liver Cirrhosis Therapeutics Customers List Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Liver Cirrhosis Therapeutics Product Image Figure 2. Global Liver Cirrhosis Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liver Cirrhosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Liver Cirrhosis Therapeutics Sales (2021-2032) & (W Units) Figure 5. Global Liver Cirrhosis Therapeutics Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Liver Cirrhosis Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Liver Cirrhosis Therapeutics Drugs Image Figure 10. Injection Liver Cirrhosis Therapeutics Drugs Image Figure 11. Global Liver Cirrhosis Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Liver Cirrhosis Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Liver Cirrhosis Therapeutics Sales Volume Share by Type (2021-2032) Figure 14. Global Liver Cirrhosis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Liver Cirrhosis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Liver Cirrhosis Therapeutics Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Other Image Figure 20. Global Liver Cirrhosis Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 21. Global Liver Cirrhosis Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Liver Cirrhosis Therapeutics Sales Volume Share by Application (2021-2032) Figure 23. Global Liver Cirrhosis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Liver Cirrhosis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Liver Cirrhosis Therapeutics Sales Value Share by Application (2021-2032) Figure 26. Global Liver Cirrhosis Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 27. Global Liver Cirrhosis Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Liver Cirrhosis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Liver Cirrhosis Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Liver Cirrhosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. North America Liver Cirrhosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Liver Cirrhosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Liver Cirrhosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Liver Cirrhosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Liver Cirrhosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Liver Cirrhosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 37. South America Liver Cirrhosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Liver Cirrhosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Liver Cirrhosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Liver Cirrhosis Therapeutics Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Liver Cirrhosis Therapeutics Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Liver Cirrhosis Therapeutics Drugs
  • Injection Liver Cirrhosis Therapeutics Drugs
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Bristol-Myers Squibb
  • Conatus Pharmaceuticals
  • Gilead Sciences
  • Gwo Xi Stem Cell Applied Technology
  • Instituto Grifols
  • Intercept Pharmaceuticals
  • NGM Biopharmaceuticals
  • Norgine
  • Pharmicell
  • Salix Pharmaceuticals
  • Stempeutics Research
  • GlaxoSmithKline
  • Roche
  • Merck
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Liver Cirrhosis Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global Liver Cirrhosis Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global Liver Cirrhosis Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Liver Cirrhosis Therapeutics Market Dynamics
  1. 2.1 Liver Cirrhosis Therapeutics Industry Trends
  2. 2.2 Liver Cirrhosis Therapeutics Industry Drivers
  3. 2.3 Liver Cirrhosis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Liver Cirrhosis Therapeutics Industry Restraints
3 Liver Cirrhosis Therapeutics Market by Company
  1. 3.1 Global Liver Cirrhosis Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Liver Cirrhosis Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Liver Cirrhosis Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global Liver Cirrhosis Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global Liver Cirrhosis Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global Liver Cirrhosis Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global Liver Cirrhosis Therapeutics Company Product Type and Application
  8. 3.8 Global Liver Cirrhosis Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Liver Cirrhosis Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Liver Cirrhosis Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Liver Cirrhosis Therapeutics Market by Type
  1. 4.1 Liver Cirrhosis Therapeutics Type Introduction
  2. 4.1.1 Oral Liver Cirrhosis Therapeutics Drugs
  3. 4.1.2 Injection Liver Cirrhosis Therapeutics Drugs
  4. 4.2 Global Liver Cirrhosis Therapeutics Sales Volume by Type
  5. 4.2.1 Global Liver Cirrhosis Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Liver Cirrhosis Therapeutics Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Liver Cirrhosis Therapeutics Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Liver Cirrhosis Therapeutics Sales Value by Type
  9. 4.3.1 Global Liver Cirrhosis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Liver Cirrhosis Therapeutics Sales Value by Type (2021-2032)
  11. 4.3.3 Global Liver Cirrhosis Therapeutics Sales Value Share by Type (2021-2032)
5 Liver Cirrhosis Therapeutics Market by Application
  1. 5.1 Liver Cirrhosis Therapeutics Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Liver Cirrhosis Therapeutics Sales Volume by Application
  6. 5.2.1 Global Liver Cirrhosis Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Liver Cirrhosis Therapeutics Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Liver Cirrhosis Therapeutics Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Liver Cirrhosis Therapeutics Sales Value by Application
  10. 5.3.1 Global Liver Cirrhosis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Liver Cirrhosis Therapeutics Sales Value by Application (2021-2032)
  12. 5.3.3 Global Liver Cirrhosis Therapeutics Sales Value Share by Application (2021-2032)
6 Liver Cirrhosis Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global Liver Cirrhosis Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Liver Cirrhosis Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Liver Cirrhosis Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global Liver Cirrhosis Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global Liver Cirrhosis Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Liver Cirrhosis Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Liver Cirrhosis Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Liver Cirrhosis Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global Liver Cirrhosis Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Liver Cirrhosis Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America Liver Cirrhosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Liver Cirrhosis Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe Liver Cirrhosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Liver Cirrhosis Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Liver Cirrhosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Liver Cirrhosis Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America Liver Cirrhosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Liver Cirrhosis Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Liver Cirrhosis Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Liver Cirrhosis Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global Liver Cirrhosis Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Liver Cirrhosis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Liver Cirrhosis Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global Liver Cirrhosis Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global Liver Cirrhosis Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global Liver Cirrhosis Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Liver Cirrhosis Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Liver Cirrhosis Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Liver Cirrhosis Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Liver Cirrhosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Liver Cirrhosis Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Liver Cirrhosis Therapeutics Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 Conatus Pharmaceuticals
  8. 8.2.1 Conatus Pharmaceuticals Company Information
  9. 8.2.2 Conatus Pharmaceuticals Business Overview
  10. 8.2.3 Conatus Pharmaceuticals Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Conatus Pharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio
  12. 8.2.5 Conatus Pharmaceuticals Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Liver Cirrhosis Therapeutics Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 Gwo Xi Stem Cell Applied Technology
  20. 8.4.1 Gwo Xi Stem Cell Applied Technology Company Information
  21. 8.4.2 Gwo Xi Stem Cell Applied Technology Business Overview
  22. 8.4.3 Gwo Xi Stem Cell Applied Technology Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Gwo Xi Stem Cell Applied Technology Liver Cirrhosis Therapeutics Product Portfolio
  24. 8.4.5 Gwo Xi Stem Cell Applied Technology Recent Developments
  25. 8.5 Instituto Grifols
  26. 8.5.1 Instituto Grifols Company Information
  27. 8.5.2 Instituto Grifols Business Overview
  28. 8.5.3 Instituto Grifols Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Instituto Grifols Liver Cirrhosis Therapeutics Product Portfolio
  30. 8.5.5 Instituto Grifols Recent Developments
  31. 8.6 Intercept Pharmaceuticals
  32. 8.6.1 Intercept Pharmaceuticals Company Information
  33. 8.6.2 Intercept Pharmaceuticals Business Overview
  34. 8.6.3 Intercept Pharmaceuticals Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Intercept Pharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio
  36. 8.6.5 Intercept Pharmaceuticals Recent Developments
  37. 8.7 NGM Biopharmaceuticals
  38. 8.7.1 NGM Biopharmaceuticals Company Information
  39. 8.7.2 NGM Biopharmaceuticals Business Overview
  40. 8.7.3 NGM Biopharmaceuticals Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 NGM Biopharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio
  42. 8.7.5 NGM Biopharmaceuticals Recent Developments
  43. 8.8 Norgine
  44. 8.8.1 Norgine Company Information
  45. 8.8.2 Norgine Business Overview
  46. 8.8.3 Norgine Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Norgine Liver Cirrhosis Therapeutics Product Portfolio
  48. 8.8.5 Norgine Recent Developments
  49. 8.9 Pharmicell
  50. 8.9.1 Pharmicell Company Information
  51. 8.9.2 Pharmicell Business Overview
  52. 8.9.3 Pharmicell Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pharmicell Liver Cirrhosis Therapeutics Product Portfolio
  54. 8.9.5 Pharmicell Recent Developments
  55. 8.10 Salix Pharmaceuticals
  56. 8.10.1 Salix Pharmaceuticals Company Information
  57. 8.10.2 Salix Pharmaceuticals Business Overview
  58. 8.10.3 Salix Pharmaceuticals Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Salix Pharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio
  60. 8.10.5 Salix Pharmaceuticals Recent Developments
  61. 8.11 Stempeutics Research
  62. 8.11.1 Stempeutics Research Company Information
  63. 8.11.2 Stempeutics Research Business Overview
  64. 8.11.3 Stempeutics Research Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Stempeutics Research Liver Cirrhosis Therapeutics Product Portfolio
  66. 8.11.5 Stempeutics Research Recent Developments
  67. 8.12 GlaxoSmithKline
  68. 8.12.1 GlaxoSmithKline Company Information
  69. 8.12.2 GlaxoSmithKline Business Overview
  70. 8.12.3 GlaxoSmithKline Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 GlaxoSmithKline Liver Cirrhosis Therapeutics Product Portfolio
  72. 8.12.5 GlaxoSmithKline Recent Developments
  73. 8.13 Roche
  74. 8.13.1 Roche Company Information
  75. 8.13.2 Roche Business Overview
  76. 8.13.3 Roche Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Roche Liver Cirrhosis Therapeutics Product Portfolio
  78. 8.13.5 Roche Recent Developments
  79. 8.14 Merck
  80. 8.14.1 Merck Company Information
  81. 8.14.2 Merck Business Overview
  82. 8.14.3 Merck Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Merck Liver Cirrhosis Therapeutics Product Portfolio
  84. 8.14.5 Merck Recent Developments
  85. 8.15 Johnson & Johnson
  86. 8.15.1 Johnson & Johnson Company Information
  87. 8.15.2 Johnson & Johnson Business Overview
  88. 8.15.3 Johnson & Johnson Liver Cirrhosis Therapeutics Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Johnson & Johnson Liver Cirrhosis Therapeutics Product Portfolio
  90. 8.15.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Liver Cirrhosis Therapeutics Value Chain Analysis
  2. 9.1.1 Liver Cirrhosis Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Liver Cirrhosis Therapeutics Sales Mode & Process
  6. 9.2 Liver Cirrhosis Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Liver Cirrhosis Therapeutics Distributors
  9. 9.2.3 Liver Cirrhosis Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst